BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11854269)

  • 1. ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain.
    Westling J; Fosang AJ; Last K; Thompson VP; Tomkinson KN; Hebert T; McDonagh T; Collins-Racie LA; LaVallie ER; Morris EA; Sandy JD
    J Biol Chem; 2002 May; 277(18):16059-66. PubMed ID: 11854269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the "aggrecanase" site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain.
    Lark MW; Gordy JT; Weidner JR; Ayala J; Kimura JH; Williams HR; Mumford RA; Flannery CR; Carlson SS; Iwata M
    J Biol Chem; 1995 Feb; 270(6):2550-6. PubMed ID: 7852317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4).
    Tortorella MD; Pratta M; Liu RQ; Austin J; Ross OH; Abbaszade I; Burn T; Arner E
    J Biol Chem; 2000 Jun; 275(24):18566-73. PubMed ID: 10751421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase.
    Mercuri FA; Doege KJ; Arner EC; Pratta MA; Last K; Fosang AJ
    J Biol Chem; 1999 Nov; 274(45):32387-95. PubMed ID: 10542281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity.
    Mercuri FA; Maciewicz RA; Tart J; Last K; Fosang AJ
    J Biol Chem; 2000 Oct; 275(42):33038-45. PubMed ID: 11032846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-d (atrolysin C) at the matrix metalloproteinase and aggrecanase sites.
    Tortorella MD; Pratta MA; Fox JW; Arner EC
    J Biol Chem; 1998 Mar; 273(10):5846-50. PubMed ID: 9488721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.
    Kashiwagi M; Enghild JJ; Gendron C; Hughes C; Caterson B; Itoh Y; Nagase H
    J Biol Chem; 2004 Mar; 279(11):10109-19. PubMed ID: 14662755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions.
    Hörber C; Büttner FH; Kern C; Schmiedeknecht G; Bartnik E
    Matrix Biol; 2000 Nov; 19(6):533-43. PubMed ID: 11068207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B.
    Fosang AJ; Neame PJ; Last K; Hardingham TE; Murphy G; Hamilton JA
    J Biol Chem; 1992 Sep; 267(27):19470-4. PubMed ID: 1326552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the 'aggrecanase' and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan.
    Büttner FH; Hughes CE; Margerie D; Lichte A; Tschesche H; Caterson B; Bartnik E
    Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):159-65. PubMed ID: 9639575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1.
    Gao G; Plaas A; Thompson VP; Jin S; Zuo F; Sandy JD
    J Biol Chem; 2004 Mar; 279(11):10042-51. PubMed ID: 14701864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites.
    Nakamura H; Fujii Y; Inoki I; Sugimoto K; Tanzawa K; Matsuki H; Miura R; Yamaguchi Y; Okada Y
    J Biol Chem; 2000 Dec; 275(49):38885-90. PubMed ID: 10986281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum.
    Lark MW; Williams H; Hoernner LA; Weidner J; Ayala JM; Harper CF; Christen A; Olszewski J; Konteatis Z; Webber R
    Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):245-52. PubMed ID: 7717983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4).
    Hashimoto G; Aoki T; Nakamura H; Tanzawa K; Okada Y
    FEBS Lett; 2001 Apr; 494(3):192-5. PubMed ID: 11311239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggrecanases and cartilage matrix degradation.
    Nagase H; Kashiwagi M
    Arthritis Res Ther; 2003; 5(2):94-103. PubMed ID: 12718749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage.
    Patwari P; Gao G; Lee JH; Grodzinsky AJ; Sandy JD
    Osteoarthritis Cartilage; 2005 Apr; 13(4):269-77. PubMed ID: 15780640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.
    Abbaszade I; Liu RQ; Yang F; Rosenfeld SA; Ross OH; Link JR; Ellis DM; Tortorella MD; Pratta MA; Hollis JM; Wynn R; Duke JL; George HJ; Hillman MC; Murphy K; Wiswall BH; Copeland RA; Decicco CP; Bruckner R; Nagase H; Itoh Y; Newton RC; Magolda RL; Trzaskos JM; Burn TC
    J Biol Chem; 1999 Aug; 274(33):23443-50. PubMed ID: 10438522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of O-linked and N-linked oligosaccharides is required for optimum detection of NITEGE neoepitope on ADAMTS4-digested fetal aggrecans: implications for specific N-linked glycan-dependent aggrecanolysis at Glu373-Ala374.
    Frank JE; Thompson VP; Brown MP; Sandy JD
    Osteoarthritis Cartilage; 2009 Jun; 17(6):777-81. PubMed ID: 19071032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.
    Sandy JD; Westling J; Kenagy RD; Iruela-Arispe ML; Verscharen C; Rodriguez-Mazaneque JC; Zimmermann DR; Lemire JM; Fischer JW; Wight TN; Clowes AW
    J Biol Chem; 2001 Apr; 276(16):13372-8. PubMed ID: 11278559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4).
    Tortorella MD; Liu RQ; Burn T; Newton RC; Arner E
    Matrix Biol; 2002 Oct; 21(6):499-511. PubMed ID: 12392761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.